GlassScriptPhysician profile
Jefrina Zaman
NPI 1598226987
$1,539.38
in general payments reported to CMS, 2019-2025
17 companies · $535 in 2025
The $535 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $195 · 2023: $91.27 · 2024: $719 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280 · Education: $63.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.46 |
| Education | $63.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $269.69 | 2024-2025 | Fasenra, Tezspire, Breztri |
| Jazz Pharmaceuticals INC. | $190.97 | 2022-2023 | Xywav |
| Merck Sharp & Dohme LLC | $174.21 | 2024-2025 | Zerbaxa, Winrevair |
| Olympus America INC. | $137.06 | 2024 | Spiration Valve System |
| Abiomed | $134.90 | 2024 | Impella |
| Glaxosmithkline, LLC. | $127.51 | 2024-2025 | Nucala, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $122.03 | 2024-2025 | Opsumit, Uptravi |
| Insmed, INC. | $105.92 | 2023-2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $87.78 | 2023-2025 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.65 | 2023-2024 | Ofev |
| Pinnacle Biologics, INC | $27.53 | 2024 | Photofrin |
| Alexion Pharmaceuticals, INC. | $22.34 | 2025 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $19.62 | 2024 | Dupixent |
| Mallinckrodt Hospital Products INC. | $15.59 | 2025 | Terlivaz |
| Emd Serono, INC. | $15.51 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $15.28 | 2024 | Giapreza |
| Harmony Biosciences LLC | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jefrina Zaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.